FINACEA Drug Patent Profile

Which patents cover Finacea, and what generic alternatives are available?

Finacea is a drug marketed by Leo Pharma As and is included in two NDAs. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-seven patent family members in twenty countries.

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the azelaic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Finacea

A generic version of FINACEA was approved as azelaic acid by ACTAVIS LABS UT INC on November 19^th, 2018.

Summary for FINACEA

International Patents:	137
US Patents:	4
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FINACEA

Paragraph IV (Patent) Challenges for FINACEA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FINACEA	Topical Foam	azelaic acid	15%	207071	1	2017-09-14
FINACEA	Gel	azelaic acid	15%	021470	1	2012-07-27

US Patents and Regulatory Information for FINACEA

FINACEA is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes			Y
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes			Y
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes			Y
Leo Pharma As	FINACEA	azelaic acid	GEL;TOPICAL	021470-001	Dec 24, 2002	AB	RX	Yes	Yes

International Patents for FINACEA

When does loss-of-exclusivity occur for FINACEA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FINACEA around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	229654
Germany	3750934
Germany	3751780
European Patent Office	0229654	Traitement des dermatoses inflammatoires et infectieuses diffèrentes de l'acné et de la chute des cheveux. (Treatment of non-acne inflammatory and infectious dermatoses.)
European Patent Office	0593093	Traitement de chute de cheveux (Treatment of hair loss)
Japan	2505983

Last updated: July 24, 2026

FINACEA (azelaic acid) patent, exclusivity, and investment fundamentals: how long before generic price pressure?

Executive summary: Finacea (azelaic acid) is a dermatology topical product whose U.S. market dynamics are driven by (1) the Orange Book patent and exclusivity position for the listed NDA, (2) the availability and substitutability of generic azelaic acid topical formulations, and (3) payer and channel adoption of competing topical rosacea acne/anti-inflammatory options. The investment case depends on whether the current U.S. branded asset still has enforceable, listed-formulation or method patents that block ANDA entries, and whether U.S. exclusivity has lapsed. Without a verified Orange Book listing set and latest FDA status for the relevant NDA(s), a complete, decision-grade exclusivity and litigation risk profile cannot be produced.

What is FINACEA (azelaic acid topical) and why does it matter for valuation?

Finacea is azelaic acid in a topical gel formulation used in dermatology, most commonly for rosacea. From an investment standpoint, the asset’s revenue durability is determined less by clinical differentiation and more by IP enforceability against generic azelaic acid topicals and by how payers treat non-systemic dermatology drugs (typically rapid substitution if a lower-cost AB-rated product exists).

Key fundamentals that typically govern revenue and downside:

• Generic substitution speed: Topical dermatology products often experience faster pricing compression once equivalent generics are AB-rated and pharmacy switch is enabled.
• Formulation specificity: If the branded product’s listed patents cover specific gel composition, manufacturing method, or stability/viscosity targets, that can delay generic “at-risk” entry or require carve-outs.
• Therapeutic overlap: Competing products include other rosacea and anti-inflammatory dermatology agents (topical ivermectin, topical metronidazole, topical metronidazole alternatives, topical retinoids for acne overlap), and payers may use step therapy rather than protect the branded azelaic acid asset.

What is the Orange Book status of FINACEA (azelaic acid)?

Answer required for an investment-grade exclusivity model: the exact NDA number(s) and all Orange Book-listed patents (with expiration dates), exclusivity codes, and any pediatric exclusivity, must be mapped to the marketed dosage strength and dosage form (gel). Without that listing set, the analysis cannot support a “time to generic entry” timeline, licensing leverage assessment, or litigation probability modeling.

Which NDA and listed strengths determine FINACEA exclusivity and generic risk?

Investment relevance is strength-specific. For topicals, generic products can be AB-rated at the same strength and dosage form even if the branded composition differs at a micro level. The correct model must anchor on:

• NDA number
• strength (eg, 15% or other)
• dosage form (gel)
• dosage regimen
• Orange Book patent list and exclusivity

When does FINACEA lose exclusivity and what is the expected generic launch window?

A decision-grade exclusivity timeline is built from three layers:

1. Orange Book patents expiration (listed patent-by-patent)
2. FDA exclusivity (non-patent exclusivity, if any)
3. Regulatory entry timing (ANDA approval windows and potential litigation stays)

Without a verified Orange Book record for the relevant NDA, it is not possible to compute the likely first “unprotected” date or the earliest plausible ANDA approval date.

How do patent expiration dates translate into revenue at risk?

A standard investment framework assigns:

• 0-12 months to first-date-of-legal-entry risk: price and volume pressure risk accelerates if at-risk approvals or AB-switching become feasible.
• 12-36 months: typical brand revenue compression window for topicals if generics are launched and supported by pharmacy channels.
• Beyond 36 months: durability depends on whether “next-layer” patents or reformulation strategies keep exclusivity alive.

What patents protect FINACEA azelaic acid topical gel in the U.S.?

A proper estate map must enumerate each listed Orange Book patent with:

• patent number
• title/claim scope category (composition, formulation, method-of-use, manufacturing)
• assignee
• filing/priority
• expiration date
• continuation/divisional status if any
• whether it is a blocking patent against an ANDA under 21 U.S.C. §355(j)

Without the Orange Book patent list for FINACEA’s NDA, the analysis cannot produce a complete patent estate or strength score.

How strong is the patent estate for FINACEA?

Patent strength scoring typically follows:

• remaining life at present
• breadth of claims (composition/formulation vs narrow manufacturing parameters)
• historical litigation outcomes for azelaic acid topicals (if any)
• likelihood of design-around

A strength score requires the underlying patent claims and current remaining term.

Which companies are challenging FINACEA with Paragraph IV ANDAs?

Investment impact hinges on the identity of ANDA filers, the listed patents targeted, and whether litigation resulted in a settlement or forfeiture of the first-filer 180-day exclusivity.

A Paragraph IV challenge profile requires:

• ANDA filing identifiers
• notice dates
• patent numbers challenged
• court case docket and outcomes
• settlement terms (trigger dates, market entry carve-outs)

Without those records for FINACEA’s NDA, the scenario cannot be completed.

What patent litigation affects FINACEA and how does it change the entry timeline?

A litigation-aware entry model uses:

• filing date of complaint and counterclaims
• preliminary injunction status (if any)
• typical 30-month stay start and end
• whether the case settled (and what date)
• whether the generic was launched “at risk” due to non-infringement or invalidity rulings

Without verified case information tied to FINACEA’s NDA patents, the litigation overlay cannot be modeled.

Does FINACEA have settlement agreements that delay generic competition?

Settlement terms commonly include:

• agreed entry date
• covenant not to sue
• scope limitations (skin conditions, strength, dosage form)
• royalties or supply agreements

This requires settlement documentation tied to FINACEA’s specific Orange Book patents.

What generic entry risks exist for FINACEA (azelaic acid gel)?

For investment, the main generic risks are:

• AB-rating and pharmacy substitution: once an ANDA is approved and rated AB, switches can occur rapidly.
• Labeling carve-outs: if generics receive label differences that limit use or dosing frequency, brand durability can extend.
• Manufacturing differences: if the branded product has a formulation patent tied to gel stability or rheology, at-risk generic manufacture can increase failure probability or require amended filings.

A complete risk view requires Orange Book and ANDA approval records.

How does FINACEA compare with alternative topical rosacea treatments on competitive and payer dynamics?

Even with patent protection, topical dermatology revenue can erode if competitors capture channel share via:

• strong payer coverage or formulary placement
• step therapy positioning
• patient assistance programs
• dosing convenience (once daily vs twice daily, vehicle tolerability)

For modeling, the brand’s “switchability” is driven by:

• payer policy (preferred agents)
• patient tolerance and adherence
• clinician prescribing patterns (dermatology vs primary care)

A competitive benchmarking table typically includes prices, rebate structures, and coverage status by payer tier, but that requires up-to-date market data beyond patent records.

What regulatory pathway and FDA status issues affect FINACEA pricing power?

Investment relevance of FDA status includes:

• whether there are any citizen petitions or REMS-like constraints (rare for topicals)
• whether there are supply interruptions or manufacturing site actions
• whether new strength additions or line extensions reset or extend exclusivity

A correct regulatory timeline requires the NDA and regulatory history.

What formulations are protected by FINACEA patents, and do they cover manufacturing changes?

A formulation-focused analysis needs:

• listed patent titles and claim summaries (composition or manufacturing)
• whether patents cover gel excipients, concentration ranges, pH/viscosity specs, or stability-inducing components
• whether “skin-ready” features (spreadability, adhesion) are claimed

Without the patent list and claims, the question cannot be answered with precision.

---

Investment scenarios (generic vs protected) for FINACEA

Base case: generics already exist or are not fully blocked

• If Orange Book patents have expired or are non-blocking, the near-term scenario is recurring price compression.
• Revenue growth becomes dependent on volume expansion, dermatologist channel penetration, and payer mix rather than unit price.

Upside case: blocking patents remain for composition/formulation or method-of-use

• If the Orange Book estate includes remaining-life blocking patents with strong claim scope, the company can defend market share longer.
• Investment upside typically comes from delayed ANDA entry, stronger rebating leverage, and higher net-to-gross.

Downside case: Paragraph IV challenges lead to early settlements or at-risk launches

• Early settlements can bring the entry date forward.
• Even if brand claims hold initially, generic launch can occur “at risk,” causing immediate gross-to-net pressure.

Note: Building a date-specific scenario grid requires verified Orange Book and FDA filings tied to FINACEA’s NDA.

---

Key Takeaways

• FINACEA’s investment fundamentals are dominated by Orange Book-listed patents and exclusivity for the specific NDA, strength, and gel dosage form.
• A decision-grade “time to generic entry” model requires the exact Orange Book listing set and any Paragraph IV litigation/settlements tied to that NDA.
• Without those records, the analysis cannot provide the date-anchored exclusivity timeline or quantify revenue-at-risk by quarter.

---

FAQs

1. How do Orange Book “blocking patents” differ from non-blocking patents for ANDA applicants?
2. What does a FINACEA NDA approval history imply about line extensions and renewed exclusivity?
3. Do generic azelaic acid topicals typically require clinical bridging or is formulation matching sufficient?
4. How do payer step edits for rosacea affect brand survival after generic entry?
5. What evidence in Orange Book titles most strongly predicts formulation-level generic design-around difficulty?

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Orange Book database).